Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy
Joanne E Davis, Sasanka M Handunnetti, Mandy Ludford-Menting, Chia Sharpe, Piers Blombery, Mary Ann Anderson, Andrew W Roberts, John F Seymour, Constantine S Tam, David S Ritchie, Rachel M Koldej
Blood Advances | AMER SOC HEMATOLOGY | Published : 2020
Combination venetoclax plus ibrutinib for the treatment of mantle cell lymphoma (MCL) has demonstrated efficacy in the relapsed or refractory setting; however, the long-term impact on patient immunology is unknown. In this study, changes in immune subsets of MCL patients treated with combination venetoclax and ibrutinib were assessed over a 4-year period. Multiparameter flow cytometry of peripheral blood mononuclear cells showed that ≥12 months of treatment resulted in alterations in the proportions of multiple immune subsets, most notably CD4+ and CD8+ effector and central memory T cells and natural killer cells, and normalization of T-cell cytokine production in response to T-cell receptor..View full abstract
This study was supported, in part, by the CLL Global Research Foundation, Wilson Centre for Lymphoma Genomics, Snowdome Foundation, and Royal Melbourne Hospital Foundation.